Peter Rossing MD, DMSc

After graduating, Peter Rossing joined the Steno Diabetes Center as a research fellow from 1991–1996, and was also Course Coordinator of the Steno Education Center from 1995–1996. After submitting his DMSc thesis, “Promotion, prediction and prevention of progression in diabetic nephropathy”, defended in 1998, he entered his clinical training at the University of Copenhagen Hospitals to obtain a specialist degree in internal medicine and endocrinology in 2004.

Currently, Rossing has rejoined the Steno Diabetes Center as Head of Research and Chief Physician. Since 2007, he has been a Chief Physician and Manager of the Steno Diabetes Center research team dedicated to research on micro- and macrovascular complications of diabetes. In epidemiological studies, he has investigated key features of the pathophysiology of the diabetic kidney at different stages. He has identified several markers for the development of diabetic nephropathy, making it possible to predict individual risk. He demonstrated that a reduction in urinary albumin excretion after the onset of antihypertensive therapy in diabetic nephropathy was the best predictor of a successful treatment outcome.

Rossing has been involved in several intervention studies in patients with overt diabetic nephropathy, aiming to improve prognosis. In addition to studies on conventional antihypertensive agents, he has been involved in some of the first studies of angiotensin II receptor blockers, aldosterone antagonists, and, most recently, studies of direct renin inhibition with Aliskiren in diabetic kidney disease.

Rossing has co-authored more than 300 papers, 19 of which are reviews or invited chapters, and his h-index is 57. Furthermore, he has presented over 300 abstracts, mainly at international meetings. He has received several national and international awards, including the Minkowski Prize from the EASD in 2005, the Novartis Young Investigator Diabetes Prize in 2009, and the Golgi Prize in 2016.